Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
SNDX-5613
Syndax Pharmaceuticals Inc
Acute Myeloid Leukemia
1 trial -
SNDX-6352
Syndax Pharmaceuticals Inc
Coronavirus
1 trial -
Venetoclax
Syndax Pharmaceuticals Inc
Acute Myeloid Leukemia
1 trial -
axatilimab
Syndax Pharmaceuticals Inc
Chronic Graft-versus-host-disease
2 trials -
entinostat
Syndax Pharmaceuticals Inc
Breast Cancer
4 trials -
entinostat
Syndax Pharmaceuticals Inc
Estrogen Receptor-negative Breast Cancer
1 trial -
entinostat
Syndax Pharmaceuticals Inc
Epithelial Ovarian Cancer
1 trial -
Axatilimab
Syndax Pharmaceuticals Inc
Solid Tumor
1 trial -
Entinostat
Syndax Pharmaceuticals Inc
Metastatic Breast Cancer
1 trial -
Entinostat
Syndax Pharmaceuticals Inc
Renal Impairment
1 trial -
Entinostat
Syndax Pharmaceuticals Inc
Pancreas Cancer
1 trial -
Entinostat
Syndax Pharmaceuticals Inc
Neoplasms
2 trials -
Entinostat
Syndax Pharmaceuticals Inc
Drug Interaction
1 trial -
Entinostat
Syndax Pharmaceuticals Inc
Fallopian Tube Cancer
1 trial -
Entinostat
Syndax Pharmaceuticals Inc
Volunteers
2 trials -
Phase 1 Study of Revumenib in Combination with Intensive Chemotherapy in Participants with AML Harboring Alterations in KMT2A/MLL, NPM1, or NUP98 Genes
Syndax Pharmaceuticals Inc
Acute Myeloid Leukemias
1 trial -
Revumenib
Syndax Pharmaceuticals Inc
Refractory Acute Myeloid Leukemia
1 trial -
Revumenib
Syndax Pharmaceuticals Inc
Acute Leukemia
1 trial -
Revumenib
Syndax Pharmaceuticals Inc
Blinatumomab
1 trial -
Revumenib
Syndax Pharmaceuticals Inc
Relapsed/Refractory Leukemias
1 trial -
SNDX-275
Syndax Pharmaceuticals Inc
Breast Cancer
1 trial -
SNDX-5613
Syndax Pharmaceuticals Inc
Acute Myeloid Leukemias
1 trial -
entinostat
Syndax Pharmaceuticals Inc
Lung Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources